Jay Manouchehri (left) is now CEO of Fluence Analytics, and co-founder Alex Reed has transitioned to president and chief commercial officer. Photo courtesy of Fluence Analytics

Teamwork makes the dream work, and a Houston-based tech startup is one step closer to its dream team, according to the company's leadership.

Fluence Analytics, which moved its headquarters to the Houston area from New Orleans last year, has named Jay Manouchehri as the company's CEO. Manouchehri has worked in leadership roles within difital transformation at ABB and Honeywell all around the world, as well as in consulting and private equity.

"As you (can see) from Jay's background he is exactly the type of person we need to help take our company the next level," says co-founder Alex Reed. "I think he's gonna be critical as we did this Houston move and go to this next phase of growth and eventually drive to an exit."

Reed has transitioned from CEO to chief commercial officer, but Manouchehri tells InnovationMap the two really lead the company together and balance each other out. Reed says he's focused on commercial product strategy and Manouchehri is leading industrial growth.

“The next step for Fluence is really that we are industrializing our product and getting it into the industrial market," Manouchehri says. "That's exactly why we moved to Houston — it's where a lot of our clients are. We're building up and structure the company in such a manner that it could scale, get the right partnerships, and hire a team to take us to the next level and deliver the technology."

Fluence's technology is changing the game within the polymer space. The industrial and laboratory monitoring solutions — a combination of software and hardware — track and report key data in real time allowing industrial polymer producers to improve process control.

"When I saw what Alex is doing, it wasn't like it's a startup looking for a problem to solve. It's a startup trying to crack a nut that a lot of people in this industry have be in trying for 20 or 30 years and haven't been able to do so," Manouchehri says.

The move to Houston has allowed the company access to new and existing customers within the industry, but also potential acquirers and the company says an exit could be possible over the next few years. Additionally, Houston provides an opportunity to expand into the biomedical space. Recently, Fluence hired a Houston employee to build out this vertical.

"MRNAs and DNAs are all polymers. So, we use the same IP and same technology and do analysis, sensing, and data analytics for the biopharma industry," Manouchehri says. "We actually are pushing that quite strongly. Our client base is growing rapidly."

Another avenue Fluence is excited about is chemical recycling or polymerization recycling. Reed says they are closely watching the traction within the circular economy.

"Imagine taking plastic bottles and being able to recycle them back to the original molecule and then reprocess them into a bottle again," Reed says. "Mechanical recycling is more typical now and has a lot of disadvantages because of the additives and the properties that you get when you melt down all the different types of plastics. (Chemical recycling) would actually allow you to make new plastic from the old plastic, just by taking the original molecule out."

Fluence Analytics, which raised a $7.5 million round led by Energy Innovation Capital last summer, has its headquarters in Stafford, just southwest of Houston.

This week's roundup of Houston innovators includes Sarah Groen of Bell & Bly Travel, Alex Reed of Fluence Analytics, and Bettina Beech of UH. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from travel to analytics— recently making headlines in Houston innovation.

Sarah Groen, founder of Bell and Bly Travel

Sarah Groen, travel entrepreneur and longtime Houston tech ecosystem member, joins the Houston Innovators Podcast. Photo courtesy of Bell and Bly Travel

It's been a scary time for travel-related businesses, and Sarah Groen has had to get innovative to maintain her business as a travel adviser. Lucky for Groen, who has a long career in tech and innovation, she had all the right pivots, including offering digital travel packages, launching a new podcast, and more.

"During COVID, a lot of businesses either shutdown or took a pause, but we accelerated," Groen says.

Groen her career on the Houston Innovators Podcast. She also gives some strategic advice for founders — like trusting your gut and reading the signs when it comes to product-market fit — on the podcast. Click here to read more and stream the episode.

Alex Reed, co-founder and CEO of Fluence Analytics

Alex Reed joined InnovationMap for a Q&A on the company's move to Houston and its growth plans. Photo courtesy of Fluence Analytics

Alex Reed watched his father work in the labs on his research as he grew up, but he realized his future wasn't in the lab. Instead, he launched a career in taking that research and turning it into a company.

Founded in 2012 in New Orleans, Fluence Analytics has entered its next phase of growth by moving its headquarters to Houston following a $7.5 million venture capital raise.

We're working with the Houston of today, but also the Houston of tomorrow," Reed tells InnovationMap in a Q&A. Click here to read more.

Bettina Beech, chief population health officer at the University of Houston

Bettina Beech is a newly named AIM-AHEAD coordinating center team member. Photo via UH.edu

The University of Houston has joined in on a national initiative to increase the diversity of artificial intelligence researchers, according to a news release from the school. Unfortunately, AI — designed by humans — mimics human decision making through its choice of algorithms. This means that the same biases humans deal with have made it into the AI decision making too. These gaps can lead to continued disparities and inequities for underrepresented communities especially in regards to health care, job hiring, and more.

"Beyond health care, AI has been used in areas from facial recognition to self-driving cars and beyond, but there is an extreme lack of diversity among the developers of AI/ML tools. Many studies have shown that flawed AI systems and algorithms perpetuate gender and racial biases and have resulted in untoward outcomes," says Bettina Beech, chief population health officer at the University of Houston and newly named AIM-AHEAD coordinating center team member.

The initiative will bring together collaborators and experts across AI and machine learning, health equity research, data science training, data infrastructure and more. The other universities involved include: University of Colorado-Anschutz Medical Center in Aurora; University of California, Los Angeles; Meharry Medical College in Nashville; Morehouse School of Medicine in Atlanta; Johns Hopkins University, and Vanderbilt University Medical Center. Click here to read more.

Alex Reed, co-founder and CEO of Fluence Analytics, joined InnovationMap for a Q&A on the company's move to Houston and its growth plans. Photo courtesy of Fluence Analytics

Fresh off $7.5M funding, this new-to-Houston tech company plans to grow and expand in life science space

q&A

Founded in 2012 in New Orleans, a tech company that provides software and hardware solutions for the chemicals industry has entered its next phase of growth by moving its headquarters to Houston following a $7.5 million venture capital raise.

Fluence Analytics, which announced its recent raise led by Yokogawa Electric Corp. last month, has officially moved to the Houston area. The company's new HQ is in Stafford. Alex Reed, co-founder and CEO of the company, joined InnovationMap for a Q&A about what led up to the move and the future of the company, which includes expanding into the life science field.

InnovationMap: Tell me about Fluence Analytics — what does the technology do and why did you decide to start the company?

Alex Reed: We have developed a patented technology that can optimize chemical production. We basically are able to measure what's happening in real time in a process. Imagine if you're baking a cake, and you follow this recipe and sometimes you get the cake you want, sometimes it's too dry, and sometimes it's not cooked enough. And so the polymers industry, for simplistic terms, has that type of an issue. You don't really know exactly where you're at your equipment behaves differently. Basically, what we're able to do is give them real-time information on what's happening as they're baking the cake so that every time they can get a perfect cake.

We have a software and hardware solution that we install in these plants to get these measurements so that our customers can optimize production — and they want to do that to improve their yield, reduce waste, increase safety, and improve quality. There are a lot of different reasons that companies are interested in our technology and we have managed to grow globally. We have customers in Asia, Europe, and the U.S.

We spun out of Tulane University. It's an interesting story because my dad is the inventor of the technology — he's a physics professor at Tulane. I grew up working in the lab with him literally since the age of 12, and I was super interested in technology and science and saw that he was working with all these chemical companies. They were always very interested in what he was working on. I got to the point where I realized that I didn't want to be a scientist — I was far more interested in the commercialization and how you go from lab to product. That transition is very difficult. So, I stepped into the role of the entrepreneur. We had the patents and technology for my dad, I had an excellent mentor, and then our other co-founder was a technical founder.

IM: When and why did you start considering an HQ move? 

AR: We raised our first institutional venture funding in April 2017. Up until that point, it was primarily working with customers and grant funding. We worked with actually a group that has an office here called Energy Innovation Capital. They came in and invested in us and supported us, and George Coyle joined our board.

So, we had that tie to Houston, and I was in Houston a lot because there was a concentration of partners and customers — and not just like chemical plant customers, but also technology and R&D centers. As we started to scale, we brought on some other investors — Mitsubishi Chemical, JSR Corp., and most recently Yokogawa Electric Corp., which has its North American headquarters in Sugar Land.

We started to just build momentum towards it. I'd say we first had the conversations pre-COVID and then COVID hit, and we'd kind of just stopped everything for a while, just to make sure we knew where the business was heading. We've made it through COVID fine and did well on coming out of it. Then we felt it was the right time to pick that thread back up. We knew it made sense. The labor pool is amazing here, and there's just so many reasons why we were looking at it. So then we just pulled the trigger.

IM: How did you decide on the Houston area? What drew you to Stafford?

AR: Initially, we had a little landing pad in the East End Maker Hub, so we got in there and they were awesome. We actually had started hiring remote people here in 2019 because we knew the move was going to happen at some point. We had a place for them to go work out of EEMH while we searched for a permanent facility. We connected with the Greater Houston Partnership, and they plugged us in to Houston Exponential, and they have been very good at introducing us to the right people. We just don't know the lay of the land to be honest, so they've been a great resource. We were looking originally on the northside of Houston, and then we saw the Stafford area. There's a huge concentration of similar type companies — automation, some software, some hardware. There were some tax advantages. We settled in the Stafford area and are very happy with the choice we made to end up here.

IM: I know you recently raised a $7.5M venture funding round. What does that funding mean for growth?

AR: Like any capital, the objective is to use it to grow. For us, "grow" has several different areas. One is the product. There's a very long roadmap of both hardware and software improvements that we want to make. So basically we're accelerating a lot of the things on our roadmap to do things like closed-loop control based on our data — imagine running a whole plant autonomously based on measurements that we're making. We're moving more and more toward that autonomous operation world and improving a lot of the actual underlying hardware, making the measurements, building out sales and marketing as we start to serve more and more customers. Product sales and marketing and customer success are the areas that we're scaling.

IM: As you grow your local team, what are you looking for?

AR: Field applications, software, some automation technicians, and more. We do have some life science applications. So, in addition to our core area on the chemical side, we have a product we've sold into biopharma, and so we want to grow some of that. We're actually hiring for a product manager for the life science side of the business. So, that one's a pretty unique opportunity and role.

IM: Considering your life science application, it seems like Houston is a good fit for that vertical as well, right?

AR: We're working with the Houston of today, but also the Houston of tomorrow, which is this life science play. The next phase is kind of following that innovation value chain. So, figuring out what's the R&D and manufacturing of these pharmaceuticals, and how you can attract more of those technology centers and factories to make the stuff here. If you look at the talent pool here, those resources are somewhat fungible with the resources that serve petrochemical and oil and gas.

This cross pollination I think actually could be quite an interesting differentiator for Houston if the city can build that critical mass. So yes, I think there is an opportunity for us to leverage this vision that Houston has for life science. Now, we'll still have to go to the coast to go to our customers, but I think talent pool, and eventually you might even have customers here. It's certainly feasible.

------

This conversation has been edited for brevity and clarity.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

Alzheimer’s research

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March.

Dr. Ryan S. Dhindsa is an assistant professor of pathology & immunology at Baylor and a principal investigator at Texas Children’s Duncan Neurological Research Institute (Duncan NRI). He hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation.

“It is an honor to receive this support from the Cure One, Cure Many Award. Viral infections are emerging as a major, underappreciated driver of Alzheimer's disease, and this award will allow our team to conduct the most comprehensive screen of viral exposures and host genetics in Alzheimer's to date, spanning over a million individuals,” Dhindsa said in a news release. “Our goal is to identify which viruses matter most, why some people are more vulnerable than others, and ultimately move the field closer to new therapeutic strategies for patients.”

Roughly 150 million people worldwide will suffer from Alzheimer’s by 2050, making it the most common cause of dementia in the world. Despite this, scientists are still at a loss as to what exactly causes it.

Dhindsa’s research is part of a new range of theories that certain viral infections may trigger Alzheimer’s. His team will take a two-fold approach. First, they will analyze the medical records of more than a million individuals looking for patterns. Second, they will analyze viral DNA in stem cell-derived brain cells to see how the infections could contribute to neurological decay. The scale of the genomic data gathering is unprecedented and may highlight a link that traditional studies have missed.

Also joining the project are Dr. Caleb Lareau of Memorial Sloan Kettering Cancer Center and Dr. Artem Babaian of the University of Toronto. Should a link be found, it would open the door to using anti-virals to prevent or treat Alzheimer’s.